Nura Bio, a biotech company based in South San Francisco, is focused on developing neuroprotective therapies to combat neurological disorders. Formerly known as Proneurotech Inc., their research aims to prevent neuronal loss and restore neuron-glia interactions, crucial for nervous system immune defense. Their flagship program targets SARM1, a key driver of axonal degeneration, which occurs in many neurological diseases. With a robust pipeline and over $140M in Series A funding, Nura Bio is dedicated to advancing treatments for central, peripheral, and ocular neurological conditions. Their innovative therapies bring hope to patients facing neurodegenerative diseases.